We propose that in the absence of RGS5 expression in HSCs, HSCs are increasingly sensitive to GPCR agonists, such as ET-1 and AngII, which contribute to HSC activation, portal hypertension, and the severity of fibrosis [14]–[19]. The gene discussed is RGS5; the disease is liver disorder.